Novo Nordisk’s shares fell after cutting full-year sales guidance, citing weakening sales of its GLP-1 drugs, Ozempic and Wegovy, facing competition from “compounders.” Despite challenges, Novo’s stock trades at a low P/E ratio. The company reduced its top-line sales and operating profit guidance due to lower-than-expected sales of Ozempic and Wegovy. The company’s stock is currently trading at one of its lowest P/E ratios in 30 years. The Motley Fool Stock Advisor team identified 10 top stocks to buy now, excluding Novo Nordisk, which could potentially yield significant returns. Don’t miss out on the latest top 10 list by joining Stock Advisor.

Read more at Yahoo Finance: Why Novo Nordisk Stock Imploded This Week